Comparing the thromboembolic risk with KRd versus VRd in newly diagnosed myeloma

(2:11)

KRd vs KTd followed by K maintenance or control for high-risk myeloma

(3:24)

KRd vs VRd as Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma

(11:6)

Should KRd-R become standard of care for high-risk SMM?

(4:2)

KRd for High-Risk Smoldering Myeloma

(4:13)

KRD vs VRD in high-risk multiple myeloma prior to autoHSCT

(1:51)

Smoldering Multiple Myeloma – Defining High Risk and Deciding Who to Treat

(30:45)

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

(5:17)

Combining carfilzomib with KRd vs KTd in NDMM patients with high-risk cytogenetics

(6:44)

KRd vs RD: Reducing Progression in High-Risk Smoldering Myeloma | Annemiek Broijl, PhD | #ASH24

(7:9)

Isatuximab, Carfilzomib, Lenalidomide, and Dex (Isa-KRd) in Pts with High-Risk Newly Diagnosed MM

(11:13)

KRD Risk Management Services, LLC | Investment Services in Plano

(51)

Can KRd + HSCT overcome the poor prognosis of harboring a high-risk cytogenetic aberration?

(3:32)

Efficacy of KRd with or without transplantation in newly diagnosed myeloma: FORTE

(3:11)

Efficacy in high-risk patients of Carfilzomib consolidation with or w/o ASCT followed by KRd or KCd

(6:46)

Can Isa-KRd achieve deep responses in high-risk NDMM, regardless of transplant eligibility?

(3:4)

ATLAS: Phase 3 Trial Comparing Post-ASCT treatment with KRd vs Post-ASCT with R maintenance

(11:47)

Four-year follow-up of GMMG-CONCEPT: efficacy of Isa-KRd in high-risk newly diagnosed myeloma

(1:28)

What are the results from the ENDURANCE trial that compares KRd to VRd in newly diagnosed patients?

(3:23)

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma

(3:45)